Florbetapir-PET image was rated as amyloid-negative in an additional nonautopsy cohort of 74 younger individuals.
“Ours are the first prospective, multicenter results that demonstrate it is possible to both directly identify and quantify the presence of β-amyloid aggregates using a molecular imaging procedure,” the researchers wrote.
Monique M.B. Breteler, MD, PhD, also commented on the importance of these findings in an editorial: “To the extent that florbetapir-PET allows an accurate assessment of β-amyloid load in the brain, it may play a crucial role in establishing the relevance of brain β-amyloid burden in the development and progression of neurodegenerative disorders including [Alzheimer’s disease].
—Ariel Jones